CDKN2B-AS1 and familial pancreatic carcinoma: We found that ANRIL was up-regulated in the tissues of pancreatic cancer, while found that ANRIL promotes cell proliferation, invasion, migration in PANC-1 and BxPC-3 cells, as well as enhances chemotherapy resistance to gemcitabine, while knockdown of ANRIL decreased those effects.